New Research Suggests Potential for Additional Clinical Utility of QIAGEN's QuantiFERON-TB Gold Plus

Thursday, April 13, 2017 Research News
Email Print This Page Comment
Font : A-A+

Findings indicate increased specificity in low-risk populations and potential for monitoring tuberculosis treatment

HILDEN, Germany, and GERMANTOWN, Maryland, April 12, 2017

/PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that two peer-reviewed studies indicate the potential additional clinical value for QuantiFERON-TB® Gold Plus (QFT-Plus®), the fourth-generation test using enhanced QuantiFERON technology to detect latent tuberculosis (TB) infection. Both studies focus on potential benefits of novel CD8+ T-cell stimulating antigens contained in QFT-Plus. A study at the Stanford University School of Medicine is the first publication describing the performance of QFT-Plus in healthcare workers, while a study at Japan's National Hospital Organization Hokkaido Medical Center provides the first evidence for QFT-Plus as a potential monitoring aid during treatment of active TB.

"These studies add to a growing body of clinical evidence on QuantiFERON-TB Plus, suggesting added utility for our novel CD8+ T-cell technology. We have introduced QFT-Plus in more than 60 markets since 2015 to aid in tuberculosis control by screening at-risk populations for latent TB infection," said Dr. Masae Kawamura, Senior Director, TB Medical and Scientific Affairs, at QIAGEN. "The unique ability of QFT-Plus to measure CD8+ immune response has led the World Health Organization to suggest that the new test offers potential for identifying patients at greater risk of progressing to active TB. A number of clinical studies are underway to explore broader applications based on the CD8+ capability, although regulatory approvals to date focus on the effectiveness of QFT-Plus in detecting latent TB infection."

Click here for the full press release

https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID={C6C448EE-E2CE-440C-A18E-ED5EA0226D34}&lang=en

Contacts:  QIAGEN  Investor Relations John Gilardi: +49-210-3291-1711 e-mail: ir@QIAGEN.com    Public Relations Dr. Thomas Theuringer: +49-210-3291-1826 e-mail: pr@QIAGEN.com

SOURCE QIAGEN N.V.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook